Advanced
  Home Compare Reports

Comparison with Similar Reports

Molecular Diagnostics Market by Product & Service(Reagents, Kits, PoC & Tabletop Instruments), Application(COVID-19, Hepatitis, HAI, HIV, Oncology, Ge...

Publisher:        MarketsandMarkets

# of Pages:        265

Rating: 

1 User License $4,950

Publication Date:  April, 2021

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
FIGURE 1 INCLUSIONS & EXCLUSIONS 34
1.2.1 MARKETS COVERED 35
FIGURE 2 MOLECULAR DIAGNOSTICS MARKET 35
1.2.2 YEARS CONSIDERED FOR THE STUDY 36
1.3 CURRENCY 36
1.4 LIMITATIONS 36
1.5 STAKEHOLDERS 36
1.6 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.2 RESEARCH APPROACH 38
FIGURE 3 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 38
2.2.1 SECONDARY DATA 39
2.2.1.1 Key data from secondary sources 39
2.2.2 PRIMARY DATA 40
2.2.2.1 Key data from primary sources 40
2.2.2.2 Key industry insights 42
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.3 MARKET SIZE ESTIMATION 43
2.3.1 BOTTOM-UP APPROACH 43
FIGURE 5 MOLECULAR DIAGNOSTICS MARKET: BOTTOM-UP APPROACH 44
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
2.3.2 TOP-DOWN APPROACH 45
FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 8 DATA TRIANGULATION METHODOLOGY 46
2.5 ASSUMPTIONS FOR THE STUDY 47
2.6 COVID-19 HEALTH ASSESSMENT 47
2.7 COVID-19 ECONOMIC ASSESSMENT 48
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 48
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 48
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 50
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN
THE MOLECULAR DIAGNOSTICS MARKET 51
3 EXECUTIVE SUMMARY 52
FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 52
FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 53
FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 53
FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 54
FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 54
FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 55
4 PREMIUM INSIGHTS 56
4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW 56
FIGURE 17 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD 56
4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 57
FIGURE 18 THE REAGENTS & KITS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021 57
4.3 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 57
FIGURE 19 THE PCR SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD 57
4.4 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 58
FIGURE 20 THE DIAGNOSTIC LABORATORIES SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE END USER MARKET DURING THE FORECAST PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 21 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
5.2.1 DRIVERS 60
5.2.1.1 The increasing prevalence of infectious diseases and cancer 60
5.2.1.2 Rising focus on R&D and funding in molecular diagnostics 60
5.2.1.3 Increasing awareness for early disease diagnosis in developing countries 61
5.2.1.4 Rising technological advancements in molecular diagnostics 61
5.2.1.5 Increasing use of PoC diagnostic tests 62
5.2.2 RESTRAINT 62
5.2.2.1 Unfavorable reimbursement scenario 62
5.2.2.2 The high cost of instruments 62
5.2.3 OPPORTUNITIES 63
5.2.3.1 The growing significance of companion diagnostics 63
5.2.3.2 Growth opportunities in emerging countries 63
5.2.4 CHALLENGES 64
5.2.4.1 Changing regulatory landscape 64
5.2.4.2 Operational barriers 64
5.2.4.3 The introduction of alternative technologies 64
5.2.5 COVID 19 IMPACT ANALYSIS 65
5.3 PRICING ANALYSIS 66
TABLE 1 PRICING ANALYSIS OF MOLECULAR DIAGNOSTIC PRODUCTS (2021) 66
5.4 PATENT ANALYSIS 67
5.5 VALUE CHAIN ANALYSIS 67
FIGURE 22 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET 67
5.6 SUPPLY CHAIN ANALYSIS 68
FIGURE 23 SUPPLY CHAIN ANALYSIS 68
5.7 ECOSYSTEM ANALYSIS 69
5.8 PORTER’S FIVE FORCES ANALYSIS 70
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS 70
5.8.1 THREAT FROM NEW ENTRANTS 70
5.8.2 THREAT FROM SUBSTITUTES 70
5.8.3 BARGAINING POWER OF BUYERS 71
5.8.4 BARGAINING POWER OF SUPPLIERS 71
5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 71
5.9 PESTLE ANALYSIS 72
5.10 REGULATORY LANDSCAPE 73
5.10.1 NORTH AMERICA 73
5.10.1.1 US 73
5.10.1.2 Canada 73
5.10.2 EUROPE 73
5.10.3 ASIA PACIFIC 73
5.10.3.1 China 73
5.10.3.2 Japan 74
5.10.3.3 India 74
5.10.4 LATIN AMERICA 74
5.10.4.1 Brazil 74
5.10.4.2 Mexico 74
5.10.5 MIDDLE EAST 75
5.10.6 AFRICA 75
5.11 TRADE ANALYSIS 75
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 75
5.11.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million) 75
5.11.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons) 76
5.12 TECHNOLOGY ANALYSIS 76
6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 77
6.1 INTRODUCTION 78
TABLE 2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 78
6.2 REAGENTS & KITS 78
6.2.1 THE RECURRENT PURCHASE OF REAGENTS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH 78
TABLE 3 REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 79
6.3 INSTRUMENTS 79
TABLE 4 INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 79
TABLE 5 INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION) 80
6.3.1 TABLETOP INSTRUMENTS 80
6.3.1.1 The outbreak of COVID-19 and rising incidences of cancer drives the growth of this segment 80
TABLE 6 TABLETOP INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION) 81
6.3.2 PORTABLE & POC INSTRUMENTS 81
6.3.2.1 The increasing adoption of PoC technologies drives the growth of this segment 81
TABLE 7 PORTABLE & POC INSTRUMENTS MARKET, BY REGION,
2019–2026 (USD MILLION) 82
6.4 SERVICES & SOFTWARE 82
6.4.1 THE GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET DRIVES SEGMENT GROWTH 82
TABLE 8 SERVICES & SOFTWARE MARKET, BY REGION, 2019–2026 (USD MILLION) 83
7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 84
7.1 INTRODUCTION 85
TABLE 9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 85
7.2 POLYMERASE CHAIN REACTION (PCR) 85
7.2.1 THE GROWING USE OF PCR IN PROTEOMICS AND GENOMICS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT 85
TABLE 10 PCR TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 86
7.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 86
7.3.1 THE COST-BENEFITS OF THIS TECHNOLOGY IS A KEY FACTOR DRIVING THE MARKET GROWTH 86
TABLE 11 INAAT TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 87
7.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 87
7.4.1 INCREASING USE OF NGS IN THE DIAGNOSIS OF CANCER IS A GROWTH DRIVER FOR THIS SEGMENT 87
TABLE 12 DNA SEQUENCING & NGS TECHNOLOGY MARKET, BY REGION,
2019–2026 (USD MILLION) 88
 
7.5 IN SITU HYBRIDIZATION (ISH) 89
7.5.1 THE RISING PREVALENCE OF CANCER AND GENETIC DISORDERS IS A KEY FACTOR DRIVING SEGMENT GROWTH 89
TABLE 13 ISH TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION) 89
7.6 DNA MICROARRAY 90
7.6.1 THE INTRODUCTION OF DNA MICROARRAY HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS 90
TABLE 14 DNA MICROARRAY TECHNOLOGY MARKET, BY REGION,
2019–2026 (USD MILLION) 90
7.7 OTHER TECHNOLOGIES 90
TABLE 15 OTHER TECHNOLOGIES MARKET, BY REGION, 2019–2026 (USD MILLION) 91
8 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 92
8.1 INTRODUCTION 93
TABLE 16 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 93
8.2 INFECTIOUS DISEASE DIAGNOSTICS 93
TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 94
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE,
2019–2026 (USD MILLION) 94
8.2.1 COVID-19 95
8.2.1.1 The outbreak of the pandemic is a key factor driving market growth 95
TABLE 19 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 95
TABLE 20 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 96
8.2.2 HEPATITIS 96
8.2.2.1 The global prevalence of hepatitis is a key factor driving market growth 96
TABLE 21 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 96
TABLE 22 HEPATITIS DIAGNOSTICS MARKET, BY REGION,
2019–2026 (MILLION ASSAYS) 97
8.2.3 CT/NG 97
8.2.3.1 CT/NG infections are the most commonly prevalent STDs; key factor driving the market growth 97
TABLE 23 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 98
TABLE 24 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 98
8.2.4 HIV 98
8.2.4.1 The increasing number of blood transfusions & donations will drive the market growth for this segment 98
TABLE 25 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 99
TABLE 26 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 99
8.2.5 HAI 99
8.2.5.1 The rising burden of MRSA infections is a key factor driving the market growth for this segment 99
TABLE 27 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 100
TABLE 28 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 100
8.2.6 HPV 100
8.2.6.1 Technological advancements such as rapid HPV diagnostics to drive the market growth for this segment 100
TABLE 29 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 101
TABLE 30 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 101
8.2.7 TUBERCULOSIS 101
8.2.7.1 The increasing burden of TB globally to drive the market growth of this segment 101
TABLE 31 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 102
TABLE 32 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION,
2019–2026 (MILLION TESTS) 102
8.2.8 INFLUENZA 103
8.2.8.1 The rising focus on containing the spread of influenza drives the market growth for this segment 103
TABLE 33 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 103
TABLE 34 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS) 103
8.2.9 OTHER INFECTIOUS DISEASES 104
TABLE 35 OTHER INFECTIOUS DISEASES MARKET, BY REGION,
2019–2026 (USD MILLION) 104
8.3 ONCOLOGY TESTING 104
TABLE 36 ONCOLOGY TESTING MARKET, BY REGION, 2019–2026 (USD MILLION) 105
TABLE 37 ONCOLOGY TESTING MARKET, BY TYPE, 2019–2026 (USD MILLION) 105
8.3.1 BREAST CANCER 105
8.3.1.1 The increasing prevalence of breast cancer is a key driver for market growth 105
TABLE 38 ONCOLOGY TESTING MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 106
8.3.2 COLORECTAL CANCER 106
8.3.2.1 The rising focus on the development of companion diagnostic assays drives the market growth 106
TABLE 39 ONCOLOGY TESTING MARKET FOR COLORECTAL CANCER, BY REGION,
2019–2026 (USD MILLION) 107
8.3.3 LUNG CANCER 107
8.3.3.1 Increasing research for lung cancer biomarkers to drive the market growth 107
TABLE 40 ONCOLOGY TESTING MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 108
8.3.4 PROSTATE CANCER 108
8.3.4.1 Advancements in genomic technologies for the development of new biomarkers drive the market growth 108
TABLE 41 ONCOLOGY TESTING MARKET FOR PROSTATE CANCER, BY REGION,
2019–2026 (USD MILLION) 109
8.3.5 OTHER CANCERS 109
TABLE 42 OTHER CANCER DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 109
8.4 GENETIC TESTS 110
8.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES 110
TABLE 43 GENETIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION) 110
8.5 OTHER APPLICATIONS 110
TABLE 44 OTHER APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 111
9 MOLECULAR DIAGNOSTICS MARKET, BY END USER 112
9.1 INTRODUCTION 113
TABLE 45 MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 113
9.2 DIAGNOSTIC LABORATORIES 113
9.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH 113
TABLE 46 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2019–2026 (USD MILLION) 114
9.3 HOSPITALS AND CLINICS 114
9.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING MARKET GROWTH 114
TABLE 47 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS,
BY REGION, 2019–2026 (USD MILLION) 115
9.4 OTHER END USERS 115
TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION) 115
10 MOLECULAR DIAGNOSTICS MARKET, BY REGION 116
10.1 INTRODUCTION 117
TABLE 49 MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION) 117
10.2 NORTH AMERICA 117
FIGURE 25 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 118
TABLE 50 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 119
TABLE 51 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 119
TABLE 52 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 119
TABLE 53 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 120
TABLE 54 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION) 120
10.2.1 US 120
10.2.1.1 The increasing prevalence of infectious diseases and cancer is a key factor expected to drive market growth in the US 120
TABLE 55 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 121
TABLE 56 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 121
TABLE 57 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 122
TABLE 58 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 122
10.2.2 CANADA 122
10.2.2.1 The availability of funding for genomics research in Canada drives the market growth 122
TABLE 59 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 123
TABLE 60 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 123
TABLE 61 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 123
TABLE 62 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 124
10.3 EUROPE 124
TABLE 63 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 125
TABLE 64 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 125
TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 125
TABLE 66 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 126
TABLE 67 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany 126
TABLE 68 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 127
TABLE 69 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 127
TABLE 70 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 128
TABLE 71 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 128
10.3.2 ITALY 128
10.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy 128
TABLE 72 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 129
TABLE 73 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 129
TABLE 74 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 129
TABLE 75 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 130
10.3.3 FRANCE 130
10.3.3.1 Rising R&D expenditure in France to drive the market growth 130
TABLE 76 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 130
TABLE 77 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 131
TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 79 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 131
10.3.4 RUSSIA 132
10.3.4.1 Increasing access to quality healthcare will support market growth in Russia 132
TABLE 80 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 132
TABLE 81 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 132
TABLE 82 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 133
TABLE 83 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 133
10.3.5 SPAIN 133
10.3.5.1 The increasing demand for genetic testing is expected to drive market growth in Spain 133
TABLE 84 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 134
TABLE 85 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
2019–2026 (USD MILLION) 134
TABLE 86 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 135
TABLE 87 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 135
10.3.6 UK 135
10.3.6.1 The increasing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK 135
TABLE 88 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 136
TABLE 89 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 136
TABLE 90 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 91 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 137
10.3.7 REST OF EUROPE 137
TABLE 92 ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 138
TABLE 93 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 138
TABLE 94 ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 138
TABLE 95 ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 139
10.4 ASIA PACIFIC 139
FIGURE 26 APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 140
TABLE 96 APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 141
TABLE 97 APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 141
TABLE 98 APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 141
TABLE 99 APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 100 APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 142
10.4.1 CHINA 142
10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth 142
TABLE 101 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 143
TABLE 102 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 143
TABLE 103 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 143
TABLE 104 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 145
10.4.2 JAPAN 145
10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan 145
TABLE 105 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 146
TABLE 106 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 146
TABLE 107 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 146
TABLE 108 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 147
10.4.3 INDIA 147
10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth 147
TABLE 109 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 148
TABLE 110 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 148
TABLE 111 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 112 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 149
10.4.4 AUSTRALIA 149
10.4.4.1 The prevalence of infectious diseases in Australia is a key driver for market growth 149
TABLE 113 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 149
TABLE 114 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 150
TABLE 115 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 116 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 150
10.4.5 REST OF ASIA PACIFIC (ROAPAC) 151
TABLE 117 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 151
TABLE 118 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 152
TABLE 119 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 152
TABLE 120 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 152
10.5 LATIN AMERICA 153
TABLE 121 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 153
TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 153
TABLE 123 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 154
TABLE 124 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 154
TABLE 125 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 154
10.5.1 BRAZIL 155
10.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the molecular diagnostics market 155
TABLE 126 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 155
TABLE 127 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 156
TABLE 128 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 156
TABLE 129 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 156
10.5.2 MEXICO 157
10.5.2.1 The improving accessibility and affordability of healthcare services to drive market growth for molecular diagnostics 157
TABLE 130 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 157
TABLE 131 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 158
TABLE 132 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 158
TABLE 133 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 158
10.5.3 REST OF LATIN AMERICA 159
TABLE 134 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 159
TABLE 135 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 159
TABLE 136 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 160
TABLE 137 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 160
10.6 MIDDLE EAST AND AFRICA 160
TABLE 138 MEA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 161
TABLE 139 MEA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 161
TABLE 140 MEA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 161
TABLE 141 MEA: MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION) 162
11 COMPETITIVE LANDSCAPE 163
11.1 OVERVIEW 163
11.2 KEY PLAYER STRATEGIES 163
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 164
11.4 MARKET SHARE ANALYSIS 165
FIGURE 28 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS (2020) 165
11.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY TECHNOLOGY 165
11.4.1.1 Polymerase Chain Reaction (PCR) 165
FIGURE 29 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 165
11.4.1.2 DNA Sequencing and NGS 166
FIGURE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 166
11.4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT) 166
TABLE 142 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY KEY PLAYERS, 2020 166
11.4.1.4 In Situ Hybridization (ISH) 166
TABLE 143 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR ISH, BY KEY PLAYERS, 2020 166
11.4.2 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY APPLICATION 167
11.4.2.1 Infectious Disease Applications 167
TABLE 144 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING,
BY KEY PLAYERS, 2020 167
11.5 COMPETITIVE LEADERSHIP MAPPING 167
11.5.1 STARS 167
11.5.2 EMERGING LEADERS 167
11.5.3 PERVASIVE PLAYERS 168
11.5.4 PARTICIPANTS 168
FIGURE 31 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 168
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME (2020) 169
11.6.1 PROGRESSIVE COMPANIES 169
11.6.2 STARTING BLOCKS 169
11.6.3 RESPONSIVE COMPANIES 169
11.6.4 DYNAMIC COMPANIES 169
FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME, 2019 170
11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS 171
FIGURE 33 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET 171
11.8 COMPETITIVE SCENARIO 171
FIGURE 34 MARKET EVALUATION MATRIX, 2018-2020 171
11.8.1 MOLECULAR DIAGNOSTICS: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2018 – MARCH 2021) 172
TABLE 145 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 172
11.8.2 MOLECULAR DIAGNOSTICS: DEALS (JANUARY 2018 – MARCH 2021) 172
TABLE 146 KEY DEALS 172
11.8.3 MOLECULAR DIAGNOSTICS: OTHER DEVELOPMENTS (JANUARY 2018 – MARCH 2021) 173
TABLE 147 OTHER KEY DEVELOPMENTS 173
12 COMPANY PROFILES 174
12.1 KEY PLAYERS 174
(Business overview, Products offered, Recent developments, SWOT analysis, Right to Win)*
12.1.1 F. HOFFMANN-LA ROCHE LTD. 174
TABLE 148 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 174
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 175
12.1.2 HOLOGIC, INC. 179
TABLE 149 HOLOGIC, INC.: BUSINESS OVERVIEW 179
FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2020) 180
12.1.3 BIOMÉRIEUX SA 184
TABLE 150 BIOMÉRIEUX SA: BUSINESS OVERVIEW 184
FIGURE 37 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 185
12.1.4 ABBOTT LABORATORIES 188
TABLE 151 ABBOTT LABORATORIES: BUSINESS OVERVIEW 188
FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 189
12.1.5 QIAGEN 193
TABLE 152 QIAGEN: BUSINESS OVERVIEW 193
FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 194
12.1.6 THERMO FISHER SCIENTIFIC INC. 199
TABLE 153 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 199
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 200
12.1.7 ILLUMINA, INC. 202
TABLE 154 ILLUMINA, INC.: BUSINESS OVERVIEW 202
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 203
12.1.8 MYRIAD GENETICS INC. 206
TABLE 155 MYRIAD GENETICS INC.: BUSINESS OVERVIEW 206
FIGURE 42 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2019) 206
12.1.9 SIEMENS HEALTHINEERS AG 209
TABLE 156 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 209
FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 210
12.1.10 DANAHER CORPORATION 212
TABLE 157 DANAHER CORPORATION: BUSINESS OVERVIEW 212
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 212
12.1.11 GRIFOLS S.A. 215
TABLE 158 GRIFOLS S.A.: BUSINESS OVERVIEW 215
FIGURE 45 GRIFOLS S.A: COMPANY SNAPSHOT (2020) 215
12.1.12 AGILENT TECHNOLOGIES INC. 217
TABLE 159 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW 217
FIGURE 46 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020) 218
12.1.13 BECTON, DICKINSON AND COMPANY 221
TABLE 160 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 221
FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 222
12.1.14 DIASORIN S.P.A 224
TABLE 161 DIASORIN S.P.A: BUSINESS OVERVIEW 224
FIGURE 48 DIASORIN S.P.A: COMPANY SNAPSHOT (2019) 225
12.2 START UP/ SME PLAYERS 228
12.2.1 QUIDEL CORPORATION 228
TABLE 162 QUIDEL CORPORATION: BUSINESS OVERVIEW 228
FIGURE 49 QUIDEL CORPORATION: COMPANY SNAPSHOT (2019) 229
12.2.2 GENETIC SIGNATURES 232
TABLE 163 GENETIC SIGNATURES: BUSINESS OVERVIEW 232
FIGURE 50 GENETIC SIGNATURES: COMPANY SNAPSHOT (2020) 232
12.2.3 MDX HEALTH 234
TABLE 164 MDX HEALTH: BUSINESS OVERVIEW 234
FIGURE 51 MDX HEALTH: COMPANY SNAPSHOT (2019) 234
12.2.4 EXACT SCIENCES 236
TABLE 165 EXACT SCIENCES: BUSINESS OVERVIEW 236
FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2019) 236
12.2.5 BIOCARTIS NV 238
TABLE 166 BIOCARTIS NV: BUSINESS OVERVIEW 238
FIGURE 53 BIOCARTIS NV: COMPANY SNAPSHOT (2019) 238
12.2.6 TBG DIAGNOSTICS LTD. 241
TABLE 167 TBG DIAGNOSTICS LTD.: BUSINESS OVERVIEW 241
FIGURE 54 TBG DIAGNOSTICS LTD.: COMPANY SNAPSHOT (2019) 241
12.2.7 GENMARK DIAGNOSTICS INC. 243
TABLE 168 GENMARK DIAGNOSTICS INC.: BUSINESS OVERVIEW 243
FIGURE 55 GENMARK DIAGNOSTICS INC.: COMPANY SNAPSHOT (2019) 243
12.2.8 LUMINEX CORPORATION 245
TABLE 169 LUMINEX CORPORATION: BUSINESS OVERVIEW 245
FIGURE 56 LUMINEX CORPORATION: COMPANY SNAPSHOT (2019) 245
12.2.9 HTG MOLECULAR DIAGNOSTICS 247
TABLE 170 HTG MOLECULAR DIAGNOSTICS: BUSINESS OVERVIEW 247
FIGURE 57 HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2019) 247
12.2.10 VELA DIAGNOSTICS 249
TABLE 171 VELA DIAGNOSTICS: BUSINESS OVERVIEW 249
12.2.11 AMOY DIAGNOSTICS CO. LTD. 252
TABLE 172 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW 252
12.2.12 MOLBIO DIAGNOSTICS PVT. LTD. 255
TABLE 173 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW 255
12.2.13 ELITECHGROUP 257
TABLE 174 ELITECHGROUP: BUSINESS OVERVIEW 257
12.2.14 SAVYON DIAGNOSTICS LTD. 260
TABLE 175 SAVYON DIAGNOSTICS LTD.: BUSINESS OVERVIEW 260
12.2.15 ABACUS DIAGNOSTICA OY 262
TABLE 176 ABACUS DIAGNOSTICS OY: BUSINESS OVERVIEW 262
12.2.16 GENEOMBIO TECHNOLOGIES PVT LTD. 263
TABLE 177 GENEOMBIO TECHNOLOGIES PVT. LTD.: BUSINESS OVERVIEW 263
*Business overview, Products offered, Recent developments, SWOT analysis, Right to Win might not be captured in case of unlisted companies.
13 APPENDIX 265
13.1 INSIGHTS FROM INDUSTRY EXPERTS 265
13.2 DISCUSSION GUIDE 266
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 269
13.4 AVAILABLE CUSTOMIZATIONS 271
13.5 RELATED REPORTS 271
13.6 AUTHOR DETAILS 272

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127